Organ Technologies Completes Funding for Next Growth Stage
NQ Score
0/100
N1 Content Completeness
0.9
AI Summary (NQ-processed)
Organ Technologies, Inc. has completed a funding round to advance the social implementation of its organ regeneration technology. The funds will be invested in R&D for 'Bio-hybrid Tooth' and hair regeneration research, strengthening business infrastructure, and domestic and international expansion. In August 2025, the company signed a consulting agreement with US-based QNova LifeSciences to prepare FDA regulatory submissions, and in February 2026, it discovered a new 'third cell' (hair follicle regeneration supporting cell).
AI Analysis
Frequently Asked Questions
- Q: What is the funding amount?
- A: The specific amount is not disclosed in the press release.
- Q: What are the main R&D projects?
- A: The Bio-hybrid Tooth and hair regeneration research using hair follicle regeneration supporting cells.
- Q: What are the US expansion plans?
- A: The company is working with QNova to prepare for FDA regulatory submission.